CEL-SCI Corporation, a biotechnology company focutilized on developing immunotherapies for cancer and other diseases, has released its 2025 10-K report. The report provides a comprehensive overview of the company’s financial performance, business operations, strategic initiatives, and the challenges it faces as it advances its lead investigational therapy, Multikine, and other product candidates.
Financial Highlights
- Operating Expenses: The company incurred operating expenses of $24.8 million for the twelve months finished September 30, 2025. This includes significant non-cash expenses accounting for approximately 27% of the operating loss.
- Net Loss: CEL-SCI reported a net loss of $25.4 million for the year finished September 30, 2025, compared to a net loss of $26.9 million in the previous year.
- Net Loss Per Common Share – Basic and Diluted: The net loss per common share decreased from $15.31 in 2024 to $6.27 in 2025, reflecting the impact of the reverse stock split and modifys in the number of shares outstanding.
Business Highlights
- Multikine Development: CEL-SCI is focutilized on developing Multikine, an investigational Phase 3 immunotherapy for head and neck cancers. Multikine is unique as it is administered before any other treatment, aiming to incite a locoregional immune response against the tumor.
- Clinical Trial Progress: Multikine has been tested in approximately 740 patients across various phases and regions, including the U.S., Canada, Europe, Israel, and Asia. The Phase III study displayed a significant survival benefit in the tarreceive population, with a 73% survival rate at five years compared to 45% in the control group.
- Regulatory Pathway: CEL-SCI is preparing for a confirmatory registration study with the FDA, focapplying on a tarreceive population of approximately 100,000 patients worldwide per year. The company aims to seek accelerated approval based on strong survival data.
- Manufacturing Facility: CEL-SCI has a dedicated manufacturing facility near Baltimore, Maryland, which has been expanded to meet expected demand for Multikine. The facility has completed commissioning and is ready for the confirmatory study.
- LEAPS Technology: CEL-SCI is also developing LEAPS (Ligand Epitope Antigen Presentation System) technology, with product candidates for rheumatoid arthritis. The development is in a preliminary stage, with a focus on Multikine approval.
- Future Outview: CEL-SCI plans to conduct a 212-patient confirmatory registration study for Multikine and is seeking regulatory approval in multiple regions, including the U.S., Canada, and Europe. The company is also exploring commercialization opportunities in Saudi Arabia and other international markets.
- Quality of Life Improvements: In the Phase 3 trial, Multikine-treated patients reported significant quality of life improvements, including reduced pain and improved ability to eat, drink, and swallow.
- Partnerships and Agreements: CEL-SCI has signed agreements with Dallah Pharma for commercialization in Saudi Arabia and with Teva Pharmaceutical for marketing in Israel and Turkey. Additional agreements exist with Orient Europharma and Byron Biopharma for distribution in various regions.
- Innotifyectual Property: CEL-SCI holds multiple patents for Multikine and LEAPS technologies, with protection in key markets. The method of manufacturing Multikine is held as a trade secret, providing competitive protection.
Strategic Initiatives
- Strategic Focus: CEL-SCI Corporation is focutilized on advancing its lead investigational therapy, Multikine, and its LEAPS technology platform. The company is pursuing regulatory approvals in multiple regions, including the United States, Canada, the United Kingdom, and Europe, and has filed a Breakthrough Medicine Designation application with the Saudi Food and Drug Authority. The company is also planning a confirmatory registration study to support marketing authorization filings.
- Capital Management: CEL-SCI has primarily financed its operations through equity offerings, convertible notes, and loans. In fiscal years 2025 and 2024, the company raised approximately $25.0 million and $21.2 million, respectively, through the sale of common stock and the exercise of warrants. The company executed a reverse stock split in May 2025, reducing the number of outstanding shares from 94,037,256 to 3,135,021. The company has not declared or paid any dividfinishs and does not have current plans to do so. The company has also engaged in lease agreements for its manufacturing facility, with significant finance lease obligations.
- Future Outview: CEL-SCI anticipates necessarying to raise additional capital to fund its confirmatory registration study, estimated to cost about $30 million, and to continue its research and development efforts. The company plans to explore corporate partnerships, debt, and equity financings to secure the necessary funds. There is substantial doubt about the company’s ability to continue as a going concern due to recurring losses and future liquidity necessarys. The company aims to achieve regulatory approvals and generate sufficient revenues to support its operations.
Challenges and Risks
- Regulatory Approval: CEL-SCI faces significant challenges in obtaining regulatory approval for its lead investigational therapy, Multikine, as none of its product candidates have been approved for sale by the FDA or any other regulatory agency. The company is heavily reliant on the success of Multikine, which is still in the clinical trial phase, and there is no assurance of obtaining marketing approval. Additionally, the company must conduct a confirmatory registration study, which is estimated to cost approximately $30 million, to support a marketing application in the United States.
- Financial Stability: CEL-SCI has incurred significant net operating losses and anticipates continuing to generate losses as it develops Multikine and other drug candidates. The company is depfinishent on raising additional capital to fund its operations and the confirmatory registration study. There is substantial doubt about CEL-SCI’s ability to continue as a going concern due to recurring losses and future liquidity necessarys. The company’s ability to raise capital is subject to market conditions, which are outside its control, and there is no assurance that sufficient capital will be raised to support its operations.
- Market Risks: CEL-SCI’s cash flow and earnings are subject to fluctuations due to modifys in interest rates on its bank accounts. The company also faces risks related to foreign currency exmodify rates, although these are considered to be immaterial. The company’s financial condition is heavily reliant on external financing, and any adverse modifys in market conditions could impact its ability to secure necessary funding.
SEC Filing: CEL SCI CORP [ CVM ] – 10-K – Dec. 23, 2025
Leave a Reply